The „Our Sponsors“ section is under construction and will be updated regularly. We thank you for your patience.
ABOUT UNIVAR SOLUTIONS
Since 2013, Univar Solutions B.V. has been the UK Marketing Authorisation Holder for Trientine Dihydrochloride 300 mg, a drug supplied for the treatment of patients with Wilson´s disease.
The company has received a centralized European Marketing Authorization for this medicine in 2019. Trientine Dihydrochloride is now available in the EU as Cufence® 200 mg.
Our Science Is Changing the Way Medicine Treats DiseaseTM
Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Our pioneering work has delivered the world’s first and only approved RNAi therapeutics—ONPATTRO® (patisiran) in 2018, GIVLAARI® (givosiran) in 2019, and OXLUMO® (lumasiran) in 2020. We are advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to Changing Tomorrow by
improving the health of people around the world. We are committed to turning innovative science into
medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing
unmet medical needs and conducting our business with ethics and integrity enables us to improve the
health of people around the world.
We focus on Oncology, Anti-infectives, Urology and Transplantation as prioritized therapeutic areas while
advancing new therapeutic areas and discovery research leveraging new technologies and modalities.
Astellas is on the forefront of healthcare change to turn innovative science into value for patients.
Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all subtypes of progressive familial intrahepatic cholestasis (PFIC), and is also being developed to treat other rare pediatric cholestatic liver diseases with Phase 3 trials in Alagille syndrome and biliary atresia, as well as an Open-label Extension (OLE) study for PFIC. In Europe, Bylvay has been approved for the treatment of PFIC and has been submitted for pricing and reimbursement approval. The Company has also initiated a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies moving ahead with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
For more information on Albireo, please visit www.albireopharma.com.
Our purpose is to reimagine medicine to improve and extend people’s lives. We use innovative science and technology to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.
ABOUT NESTLÉ HEALTH SCIENCE
Nestlé Health Science: Empowering healthier lives through nutrition
Nestlé Health Science is a leader in the field of nutritional science, committed to redefining the management of health. We offer an extensive portfolio of science-based consumer health, medical nutrition and supplement brands.
We believe in empowering healthier lives through nutrition. Our extensive research network, both within Nestlé’s R&D centers as well as with external partners, provides the foundation for products that can help people to live their healthiest lives.
Nutrition can be life-transforming for those who need extra support during short- or long-term medical challenges, and it can enhance the quality of life of those who are already healthy. From babies and children with indications like food allergies, dysphagia, malnutrition, gastrointestinal diseases or impairments to the most senior citizens who have difficulty maintaining the right levels of nutrition; from children whose medical conditions require tube-feeding, to patients who need extra nourishment while hospitalized; and from people who are seeking to maintain a healthy weight, to those who want the support of daily vitamins and supplements to fill in the gaps in their diets, our products are designed for people across the spectrum of life.
Our commitment to science-based products means that we provide nutritional solutions that can make a real difference in the quality of life of customers, patients and caregivers.
Nestlé Health Science (Germany) GmbH
Lyoner Strasse 23
D-60523 Frankfurt / Main
0800 – 100 16 35